Advertisement
Screener

CRISPR THERAPEUTICS AG (CRSP) Graph

CRSP Revenue Flow

Filed revenue amounts for 2026-04-01 to 2026-06-30. Coverage is partial. Unconnected amounts are separate disclosures; they must not be added together.

  • 2026-06-30: Revenue $10.18M; Research and development $67.15M; Operating expenses $127.45M; Income tax $960.00K.
  • 2026-03-31: Revenue $1.46M; Research and development $68.57M; Operating expenses $131.71M; Income tax $839.00K.
  • 2025-12-31: Revenue $864.00K*; Research and development $83.53M*; Operating expenses $155.63M*; Income tax $614.00K*.
  • 2025-09-30: Revenue $889.00K; Research and development $58.90M; Operating expenses $132.95M; Income tax $619.00K.

Counterparty Name

Separate filed amounts; connecting flows are not established. Components and totals may overlap.

CRSP revenue flowFiled amounts. Only explicit calculation relationships connect amounts; dimensional membership alone does not establish an additive flow.Vertex Pharmaceuticals IncorporatedAnd Its Certain Subsidiaries$0.00Revenue$10.18MOperating expenses$127.45MOperating income-$117.27MOther income, net$27.08MResearch & development$67.15MPre-tax income-$90.19MNet income-$91.15M

Product or service

Separate filed amounts; connecting flows are not established. Components and totals may overlap.

CRSP revenue flowFiled amounts. Only explicit calculation relationships connect amounts; dimensional membership alone does not establish an additive flow.Grant$181.00KCollaboration Revenue$10.00MRevenue$10.18MOperating expenses$127.45MOperating income-$117.27MOther income, net$27.08MResearch & development$67.15MPre-tax income-$90.19MNet income-$91.15M

Finer product or service dollar figures and nonoverlapping groupings are shown only where supported by the retained filing evidence. Growth percentages are never converted to revenue dollars.

Historical revenue and expense breakdown

Revenue and expense 3 month

Period endRevenueResearch and developmentOperating expensesIncome taxNet income
2026-06-30$10.18M$67.15M$127.45M$960.00K-$91.15M
2026-03-31$1.46M$68.57M$131.71M$839.00K-$122.93M
2025-12-31$864.00K*$83.53M*$155.63M*$614.00K*-$130.61M*
2025-09-30$889.00K$58.90M$132.95M$619.00K-$106.44M
2025-06-30$892.00K$69.89M$230.22M$1.29M-$208.55M
2025-03-31$865.00K$72.48M$149.29M$1.11M-$136.00M
2024-09-30$602.00K$82.16M$110.73M$876.00K-$85.94M
2024-06-30$517.00K$80.17M$151.78M$1.29M-$126.41M
2024-03-31$504.00K$76.17M$141.09M$724.00K-$116.59M
2023-09-30$0.00$90.70M$132.41M$412.00K-$112.15M
2023-06-30$70.00M$101.56M$165.22M$923.00K-$77.74M
2023-03-31$100.00M$99.94M$164.49M$1.32M-$53.06M
2022-09-30$94.00K$116.62M$182.48M-$575.00K-$174.55M
2022-06-30$158.00K$123.22M$183.42M$6.12M-$185.83M
2022-03-31$940.00K$118.25M$176.91M$3.61M-$179.22M
2021-09-30$824.00K$83.50M$129.67M-$595.00K-$127.15M
2021-06-30$900.70M$82.33M$138.08M$4.14M$759.23M
2021-03-31$539.00K$70.62M$115.08M$575.00K-$113.16M
2020-12-31$370.00K(m)$108.13M(m)-$107.04M
2020-09-30$148.00K$71.01M$92.55M$200.00K-$92.44M
2020-06-30$44.00K$59.38M$80.73M$379.00K-$79.66M
2020-03-31$157.00K$54.19M$73.74M$377.00K-$69.73M
2019-12-31$77.02M(m)$66.03M(m)$30.54M
2019-09-30$211.93M$57.25M$72.77M$274.00K$138.42M
2019-06-30$318.00K$39.53M$55.30M$85.00K-$53.70M
2019-03-31$328.00K$33.82M$48.75M$85.00K-$48.41M
2018-12-31$115.00K(m)$45.34M(m)-$47.59M
2018-09-30$563.00K$39.82M$49.99M$137.00K-$50.71M
2018-06-30$1.09M$25.63M$38.37M$96.00K-$38.38M
2018-03-31$1.36M$19.52M$28.36M$86.00K-$28.30M
2017-12-31$32.33M(m)$31.35M(m)$140.00K
2017-09-30$2.39M$17.84M$25.96M$707.00K-$24.71M
2017-06-30$3.58M$17.12M$24.89M$343.00K-$22.32M
2017-03-31$2.70M$14.80M$23.45M$279.00K-$21.48M
2016-12-31$2.34M(m)$27.65M(m)$17.10M
2016-09-30$1.55M$12.05M$16.16M$8.00K-$14.68M
2016-06-30$795.00K$8.60M$17.35M$0.00-$17.16M
2016-03-31$476.00K$6.01M$12.13M$76.00K-$8.44M
2015-12-31$247.00K(m)$12.41M(m)-$12.27M
2015-09-30(m)$3.75M$6.20M$153.00K-$6.35M
2015-06-30(m)(m)$3.63M(m)-$3.64M
2015-03-31(m)(m)$3.74M(m)-$3.24M

Revenue and expense 6 month

Period endRevenueResearch and developmentOperating expensesIncome taxNet income
2026-06-30$11.64M$135.73M$259.16M$1.80M-$214.09M
2025-06-30$1.76M$142.38M$379.50M$2.40M-$344.55M
2024-06-30$1.02M$156.34M$292.87M$2.01M-$243.00M
2023-06-30$170.00M$201.49M$329.71M$2.24M-$130.81M
2022-06-30$1.10M$241.47M$360.33M$9.73M-$365.05M
2021-06-30$901.24M$153.97M$253.16M$4.72M$646.06M
2020-06-30$201.00K$113.57M$154.48M$756.00K-$149.39M
2019-06-30$646.00K$73.36M$104.05M$170.00K-$102.11M
2018-06-30$2.45M$45.15M$66.73M$182.00K-$66.68M
2017-06-30$6.29M$31.93M$48.34M$622.00K-$43.79M
2016-06-30$1.27M$14.61M$29.48M$76.00K-$25.60M

Revenue and expense 9 month

Period endRevenueResearch and developmentOperating expensesIncome taxNet income
2025-09-30$2.65M$201.28M$512.45M$3.02M-$450.99M
2024-09-30$1.62M$238.50M$403.60M$2.89M-$328.94M
2023-09-30$170.00M$292.19M$462.12M$2.65M-$242.96M
2022-09-30$1.19M$358.09M$542.81M$9.15M-$539.60M
2021-09-30$902.06M$237.47M$382.84M$4.12M$518.91M
2020-09-30$349.00K$184.58M$247.02M$956.00K-$241.83M
2019-09-30$212.57M$130.60M$176.82M$444.00K$36.32M
2018-09-30$3.01M$84.97M$116.72M$319.00K-$117.39M
2017-09-30$8.67M$49.77M$74.29M$1.33M-$68.50M
2016-09-30$2.82M$26.67M$45.64M$84.00K-$40.28M
2015-09-30(m)$6.40M$13.56M-$63.00K-$13.23M

Revenue and expense 12 month

Period endRevenueResearch and developmentOperating expensesIncome taxNet income
2025-12-31$3.51M$284.81M$668.08M$3.63M-$581.60M
2024-12-31$37.31M$310.24M$503.88M$3.59M-$366.25M
2023-12-31$371.21M$387.33M$593.74M$2.89M-$153.61M
2022-12-31$1.20M$461.64M$674.36M-$325.00K-$650.17M
2021-12-31$914.96M$340.57M$541.43M$1.87M$377.66M
2020-12-31$719.00K$221.38M$355.15M$809.00K-$348.87M
2019-12-31$289.59M$179.36M$242.85M$448.00K$66.86M
2018-12-31$3.12M$113.77M$162.07M$553.00K-$164.98M
2017-12-31$41.00M$69.80M$105.64M$1.75M-$68.36M
2016-12-31$5.16M$42.24M$73.29M$484.00K-$23.18M
2015-12-31$247.00K$12.57M$25.98M$7.00K-$25.50M
2014-12-31(m)$1.51M$6.63M-$63.00K-$7.01M

Similar stocks

Stock NameCountryMarket CapPE Ratio
IOVANCE BIOTHERAPEUTICS, INC. (IOVA)United States$4.897B-6.51
Scholar Rock Holding Corp (SRRK)United States$5.920B-16.37
Adaptive Biotechnologies Corp (ADPT)United States$4.719B-53.43
CG Oncology, Inc. (CGON)United States$6.095B-27.95
Relay Therapeutics, Inc. (RLAY)United States$3.884B-14.30
Immunovant, Inc. (IMVT)United States$7.028B-14.78
Tarsus Pharmaceuticals, Inc. (TARS)United States$3.329B-58.60
Denali Therapeutics Inc. (DNLI)United States$3.274B-8.04
Beam Therapeutics Inc. (BEAM)United States$2.549B-41.51
Greenland Mines Ltd (GRML)United States$2.362B